North America Diabetic Assays Market, By Type (Assays, Devices, Consumables), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Deployment (Automated, Manual), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
North America Diabetic Assays Market Analysis and Size
Diabetes is one of the most severe endocrine diseases. Around 425 million people in North America suffer from this disease. Rising incidence of diabetes and awareness towards it increases the market growth. For instance, World Health Organization (WHO) expected that there were around 125 million people aged 80 years or older and estimated to be almost 2 billion by the year 2050 in 2018. The demand for diabetes assays is being boosted by the need for easier, economic, and efficient management of the North America diabetes epidemic and increasing development of non-invasive techniques
Data Bridge Market Research analyses a growth rate in the diabetic assays market in the forecast period 2023-2030. The expected CAGR of diabetic assays market is tend to be around 4.80% in the mentioned forecast period. The market is valued at USD 1.16 billion in 2022, and it would grow upto USD 1.7 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Diabetic Assays Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Assays, Devices, Consumables), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Deployment (Automated, Manual), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America
Market Players Covered
Amgen Inc., Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (U.S.), Merck & Co., Inc. (U.S.), Abbott (U.S.), Siemens Healthcare GmbH (Germany), Hologic, Inc. (U.S.), Dynatronics Corporation (U.S.), Biomerieux (France), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Quotient Suisse SA (Switzerland), BAG Health Care GmbH (Germany), DiaSorin S.p.A (Italy), DRG INSTRUMENTS GMBH (Germany), PTS Diagnostics (U.S.), Ortho Clinical Diagnostics (U.S.), Diazyme Laboratories, Inc (U.S.), ETHOS BIOSCIENCES (U.S.), Abnova Corporation (Taiwan), Monobind Inc. (U.S.)
Diabetics assays such as auto-antibody assay, Electro-Chemiluminescence assays, enzyme inhibition assay, ELISA assay and others are widely used for the diabetes diagnosis. Diabetics cause severe damage to the heart, eyes, blood vessels, kidney and nerves. Increased risk of cardiac disorders related with diabetes requires successful testing and diagnosis options. Diabetics assays are widely used for diagnostics and monitoring who are at higher risk of developing diabetes.
North America Diabetic Assays Market Dynamics
- Increasing Technological Advancements
Rising adoption of insulin delivery devices and increasing occurrence of diabetes are boosting the market growth. Several key manufacturers are primarily focusing on technological innovations and development of different advanced products to gain a considerable market share. For instance, Novo Nordisk collaborated with Abbott in 2019 to incorporate its prefilled and durable connected pens directly into the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). CGM is said to further collaborate with insulin delivery systems to ensure a single integrated system for efficient diabetes care management. Additionally, Diabetes Care launched its Slim X2 insulin pump, which is involved with Dexcom G6 CGM. Likewise, Ypsomed Holdings developed a CGM system called Mylife Unio Neva, that adds with the company’s insulin pump. Thus, this factor increases the market growth.
- Wide Adoption of Blood Glucose Meters
The increasing adoption of blood glucose meters is slowly increasing because of advantages such as portability and accuracy. Several market players are also primarily focusing on developing these devices and are launching small blood glucose meters. Some of the smallest blood glucose meters with advanced technology are widely available in the U.K. These are Abbott Diabetes Care Freestyle Lite, Lifescan’s One Touch UltraEasy, Bayer’s CONTOUR NEXT USB, Accu-Chek Aviva Nano, TRUEone blood glucose meter and Accu-Chek Mobile. Introducing these small, discreet, and easy-to-use blood glucose meters is anticipated to increase segment growth in the upcoming years. This as a result, increases the demand for the market.
- Rising Cases of Diabetes and Obesity
Rise in prevalence of diabetes because of aging, obesity, and unhealthy lifestyle is one of the primary factors leading to the growth of the market. Obesity is a major factor leading to diabetes. According to World Health Organization, in 2016, more than 1.9 billion adults were overweight, of which, about 650 million people were obese. Several risk factors, such as obesity and overweight, are causing an increase in the prevalence of diabetes. Thus, risk factors such as overweight, obesity, smoking, and high cholesterol levels are anticipated to boost the prevalence of diabetes, thus fuelling the need for diabetes devices.
- High Cost of Treatment
The increasing expenditure associated with the glucose meters and other instruments and the cost required to conduct the assays impede the market growth. Numerous drugs and surgeries cost high, and people in highly developing and underdeveloped countries cause the under treatment of numerous patients. This impedes the market growth.
This diabetic assays market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic assays market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In 2019, Abbott (U.S.) launched its first rapid point-of-care HbA1c test to diagnose diabetes “Afinion HbA1c Dx assay” for use on Afinion AS100 Analyzer and Afinion 2 Analyzer. The Afinion HbA1c Dx assay is the first and rapid point-of-care method approved by the U.S. FDA to support various healthcare professionals in diagnosing and treating diabetes. This launch will enhance the product portfolio and user base of the company.
- In 2019, Beckman Coulter, Inc, hemoglobin A1c (HbA1c) Advanced assay received CE Mark Certification and the U.S. FDA 501(k) Clearance. The company will provide initial diagnosis of diabetes and will also aid the clinically operative outcomes.
North America Diabetic Assays Market Scope
The diabetic assays market is segmented on the basis of type, disease type, deployment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Diabetic Assays Market Regional Analysis/Insights
The diabetic assays market is analyzed and market size insights and trends are provided by type, disease type, deployment, end-users and distribution channel as referenced above.
The major countries covered in the diabetic assays market report are the U.S., Canada and Mexico in North America.
U.S. has been witnessing a positive growth for diabetic assays market throughout the forecasted period due to the increasing prevalence cases of diabetes in the U.S population that requires high detection of diabetes assays for the increasing identification and detection of diabetes diseases. For instance, United Nation anticipated that 1 out of 5 diabetes patients are above 65 years old in 2017. The increasing diabetes cases among the elderly population in U.S. is leading the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Diabetic Assays Market Share Analysis
The diabetic assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic assays market.
Key players operating in the diabetic assays market include:
- Abbvie, Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Pfizer Inc (U.S.)
- Merck & Co., Inc. (U.S.)
- Abbott (U.S.)
- Siemens Healthcare GmbH (Germany)
- Hologic, Inc. (U.S.)
- Dynatronics Corporation (U.S.)
- Biomerieux (France)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Quotient Suisse SA (Switzerland)
- BAG Health Care GmbH (Germany)
- DiaSorin S.p.A (Italy)
- DRG INSTRUMENTS GMBH (Germany)
- PTS Diagnostics (U.S.)
- Ortho Clinical Diagnostics (U.S.)
- Diazyme Laboratories, Inc (U.S.)
- ETHOS BIOSCIENCES (U.S.)
- Abnova Corporation (Taiwan)
- Monobind Inc. (U.S.)